NM
IOBT

Newtyn Management’s IO Biotech IOBT Stock Holding History

Newtyn Management’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-49,346
Closed -$92.3K – 62
2023
Q1 		$92.3K Sell
49,346
-40,654
-45% -$101K 0.02% 75
2022
Q4 		$207K Sell
90,000
-10,000
-10% -$26.5K 0.04% 66
2022
Q3 		$271K Buy
+100,000
New +$371K 0.06% 71

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AAM
Aureus Asset Management Boston, Massachusetts $1.5B AUM 20.3% 1-Year Est. Return

Newtyn Management's IOBT Position: Q2 2023 in Review

Newtyn Management sold out of IO Biotech (IOBT) in Q2 2023, closing a stake of 49,346 shares — an estimated $92.3K sold.

Newtyn Management first reported a position in IOBT in Q3 2022 and held it in 3 quarters. The position peaked at $271K in Q3 2022. 15 funds tracked by Wall St. Rank hold IOBT as of Q2 2023.

  • Newtyn Management reported no remaining IO Biotech position as of Q2 2023 after selling out during the quarter.
  • Newtyn Management sold 49,346 IO Biotech shares in Q2 2023, an estimated $92.3K.
  • Newtyn Management first reported a position in IO Biotech in Q3 2022 and held it in 3 quarters.
  • Newtyn Management's IO Biotech position peaked at $271K in Q3 2022.
  • 15 funds tracked by Wall St. Rank held IO Biotech as of Q2 2023.

Based on Newtyn Management's 13F filing for Q2 2023, filed 14 Aug 2023.